CUL4A and metabolic dysfunction-associated steatotic liver disease: Our results confirmed that LINC01468 increases CUL4A-mediated degradation of SHIP2, by which SHIP2 negatively regulates PI3K/Akt, thereby promoting lipogenesis and HCC progression; thus, SHIP2 functions as a tumor suppressor in NAFLD-HCC.